News from CROI 2011

aidsmap news from CROI 2011

Treatment monitoring: no clear benefit to adding viral load to CD4 or clinical symptoms in Thailand and Africa

Viral load is probably not essential for determining when to switch to second-line treatment in low- and middle-income settings, two large randomised trials conducted in Thailand and Cameroon

Published
01 March 2011
By
Keith Alcorn
Attachment inhibitor BMS-663068 potent and well-tolerated in early study

A novel type of drug that targets the first step of HIV entry into cells appeared safe and demonstrated good antiviral activity in a phase 2a study presented

Published
01 March 2011
By
Liz Highleyman
Zinc finger gene therapy produces HIV-resistant CD4 T-cells

Gene therapy that interferes with co-receptors on the surface of T-cells can protect these cells from HIV infection, representing a potential first step toward achieving a "functional cure", researchers

Published
01 March 2011
By
Liz Highleyman
Vaginal microbicides may not be safe for rectal use: gels being reformulated

A gel, used as a vaginal microbicide, when used rectally showed signs of efficacy, but raised safety concerns, the 18th Conference on Retroviruses and Opportunistic

Published
01 March 2011
By
Gus Cairns
One dose of raltegravir gel three hours after sex might prevent HIV infection

A study presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston has found that a single dose of a microbicide gel containing the

Published
01 March 2011
By
Gus Cairns
Antiretroviral treatment in TB patients: patients with CD4 counts below 50 need to start ART quickly

Starting HIV treatment within two weeks of tuberculosis (TB) treatment is most necessary in patients with CD4 counts below 50 cells/mm3, while a slightly longer delay does

Published
28 February 2011
By
Keith Alcorn
Truvada PrEP remains effective against HIV with 3TC/FTC resistance in animal study

The US Centers for Disease Control (CDC) has found that oral pre-exposure prophylaxis (PrEP) using a combined tenofovir/FTC (Truvada) pill is still effective against HIV with the

Published
28 February 2011
By
Gus Cairns
Self-testing for HIV proves highly acceptable in Malawi

Self-testing for HIV under supervision using an oral test proved highly acceptable in Malawi, and could form the basis for wider and more regular testing in countries severely

Published
28 February 2011
By
Keith Alcorn
Five years on from circumcision trial, nine in ten participants are circumcised and HIV incidence is two-thirds lower

Five years after the ending of one of the three big randomised controlled trials of male circumcision as an HIV prevention measure, four out of five men

Published
28 February 2011
By
Gus Cairns
← Prev123Next →

The search for a cure

Zinc finger gene therapy produces HIV-resistant CD4 T-cells.

Read this news story >

Subscribe now

Email bulletins from NAM

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.